Eversana has bought HVH Precision Analytics, bringing on its analytics platform to the corporate’s choices for the life-sciences industries. Originally designed for navy and intelligence functions, the platform has been tailor-made to be used within the healthcare sector.
Previously owned by Havas Health & You and Perspecta, HVH Precision Health appealed to Eversana due to its life-science expertise and analytics capabilities, in line with Brigham Hyde, president of Eversana’s Data and Analytics enterprise unit.
“Their prediction-based platform is the most robust in the industry, and well known for its expertise in rare disease,” Hyde informed Outsourcing-Pharma. “It has the ability to bring together millions of data sources to provide tremendous insights to our clients and their patients on different conditions to ultimately help inform treatment options.”
The potential to quickly and successfully analyze health information collected from quite a lot of sources is essential, Hyde added, particularly as adoption of synthetic intelligence (AI), machine studying (ML) and different superior applied sciences turns into extra widespread.
“Most AI and ML platform solutions are disjointed from the services and interfaces that create meaningful impact for patients. By providing a prediction platform, built on integrated patient data, combined with our best-in-class patient engagement solutions, commercial services, market access, and distribution, we have the ability to make predictions and take actions within the same organization and deliver value to stakeholder,” Hyde stated.
According to Steve Costalas, CEO of HVH Precision Analytics, sturdy information and analytics expertise are sorely wanted within the pharmaceutical trade.
“Our technology and talented team are at the forefront of the industry and are already propelling faster analysis and actions for EVERSANA clients. The fit is seamless, and we are onboarding new programs right now,” he stated.
HVH Precision Analytics reportedly will transition to the Eversana model within the coming quarter, and the corporate’s management staff will report back to Hyde. Financial particulars of the transaction weren’t disclosed.